Effect of paclitaxel in gefitinib-resistant non-small cell lung cancer (NSCLC) treatment during the COVID-19 pandemic.

被引：0
|
作者：
Mohiuddin, Md [1 ]
Kasahara, Kazuo [1 ]
机构：
[1] Kanazawa Univ, Dept Resp Med, Kanazawa, Ishikawa, Japan
来源：
CLINICAL CANCER RESEARCH | 2020年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P27
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Deoxypodophyllotoxin Inhibits Cell Growth and Induces Apoptosis by Blocking EGFR and MET in Gefitinib-Resistant Non-Small Cell Lung Cancer
    Kim, Han Sol
    Oh, Ha-Na
    Kwak, Ah-Won
    Kim, Eunae
    Lee, Mee-Hyun
    Seo, Ji-Hye
    Cho, Seung-Sik
    Yoon, Goo
    Chae, Jung-Il
    Shim, Jung-Hyun
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2021, 31 (04) : 559 - 569
  • [32] Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
    Araki, Takuya
    Yashima, Hideaki
    Shimizu, Kimihiro
    Aomori, Tohru
    Hashita, Tadahiro
    Kaira, Kyoichi
    Nakamura, Tomonori
    Yamamoto, Koujirou
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [33] Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
    Sudo, Makoto
    Mori, Seiichi
    Madan, Vikas
    Yang, Henry
    Leong, Geraldine
    Koeffler, H. Phillip
    ONCOTARGET, 2015, 6 (02) : 814 - 824
  • [34] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [35] Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
    Bae, Song Yi
    Hong, Ji-Young
    Lee, Hye-Jung
    Park, Hyen Joo
    Lee, Sang Kook
    ONCOTARGET, 2015, 6 (12) : 10146 - 10160
  • [36] Antitumor Impact of p14ARF on Gefitinib-Resistant Non-Small Cell Lung Cancers
    Saito, Ken
    Takigawa, Nagio
    Ohtani, Naoko
    Iioka, Hidekazu
    Tomita, Yuki
    Ueda, Ryuzo
    Fukuoka, Junya
    Kuwahara, Kazuhiko
    Ichihara, Eiki
    Kiura, Katsuyuki
    Kondo, Eisaku
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (08) : 1616 - 1628
  • [37] Gefitinib Plus Paclitaxel after Failure of Gefitinib in Non-small Cell Lung Cancer Initially Responding to Gefitinib
    Shukuya, Takehito
    Takahashi, Toshiaki
    Tamiya, Akihiro
    Ono, Akira
    Igawa, Satoshi
    Nakamura, Yukiko
    Tsuya, Asuka
    Murakami, Haruyasu
    Naito, Tateaki
    Kaira, Kyoichi
    Endo, Masahiro
    Yamamoto, Nobuyuki
    ANTICANCER RESEARCH, 2009, 29 (07) : 2747 - 2751
  • [38] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [39] Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer
    Sun, Ruifang
    Liu, Zhigang
    Wang, Lumin
    Lv, Weidong
    Liu, Jia
    Ding, Caixia
    Yuan, Yong
    Lei, Guangyan
    Xu, Changfu
    TUMOR BIOLOGY, 2015, 36 (09) : 7195 - 7204
  • [40] Impact of COVID-19 Pandemic on Proportion and Treatment Patterns for Stage I Non-small Cell Lung Cancer in the Netherlands
    Wolfhagen, N.
    Smit, H. J.
    Schuurbiers, O. C.
    Belderbos, J. S. A.
    Verhagen, A. F. T. M.
    Schreurs, H. W. H.
    Damhuis, R. A.
    Heineman, D. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S18 - S19
12345